Do analysts recommend TXMD or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend EGRX or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SNOA or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SNOA or UPC?

Sonoma Pharmaceuticals has higher revenue and earnings than Universe Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sonoma Pharmaceuticals $19.53M 0.30 -$3.17M -$1.22 N/A Universe Pharmaceuticals $17.86M 1.26 -$3.67M N/A N/A

Do analysts prefer COCP or SNOA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer LPCN or SNOA?

Lipocine currently has a consensus price target of $4.00, indicating a potential upside of 95.12%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lipocine is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.22 -0.02 (-1.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 +0.06 (+5.33%)

As of 07:49 PM Eastern

Compare

SNOA vs. TXMD, EGRX, UPC, COCP, and LPCN

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? Sonoma Pharmaceuticals's main competitors and comparable companies include TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Universe Pharmaceuticals (UPC), Cocrystal Pharma (COCP), and Lipocine (LPCN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

TherapeuticsMD has a net margin of -6.64% compared to Sonoma Pharmaceuticals' net margin of -10.33%. TherapeuticsMD's return on equity of -1.09% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

TherapeuticsMD has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.85	-$570K	$0.02	102.50
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.22	N/A

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, TherapeuticsMD's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Sonoma Pharmaceuticals	Neutral

Summary

TherapeuticsMD beats Sonoma Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eagle Pharmaceuticals has higher revenue and earnings than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.05	$35.64M	$1.18	0.82
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.22	N/A

In the previous week, Eagle Pharmaceuticals had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Eagle Pharmaceuticals and 0 mentions for Sonoma Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Sonoma Pharmaceuticals	Neutral

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Eagle Pharmaceuticals' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Summary

Eagle Pharmaceuticals beats Sonoma Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Universe Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Universe Pharmaceuticals and 0 mentions for Sonoma Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.98 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Neutral
Universe Pharmaceuticals	Positive

Sonoma Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Universe Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.22	N/A
Universe Pharmaceuticals	$17.86M	1.26	-$3.67M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Universe Pharmaceuticals' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats Sonoma Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Cocrystal Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Sonoma Pharmaceuticals. Cocrystal Pharma's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Sonoma Pharmaceuticals	Neutral

Sonoma Pharmaceuticals has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.22	N/A

Summary

Cocrystal Pharma beats Sonoma Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Lipocine had 9 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 9 mentions for Lipocine and 0 mentions for Sonoma Pharmaceuticals. Lipocine's average media sentiment score of 0.75 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Overall Sentiment
Lipocine	Positive
Sonoma Pharmaceuticals	Neutral

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.53	-$9.63M	-$1.79	N/A
Sonoma Pharmaceuticals	$19.53M	0.30	-$3.17M	-$1.22	N/A

Lipocine has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Lipocine currently has a consensus price target of $4.00, indicating a potential upside of 95.12%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lipocine is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has a net margin of -10.33% compared to Lipocine's net margin of -755.39%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%

Summary

Lipocine and Sonoma Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.94M	$12.12B	$7.17B	$13.38B
Dividend Yield	N/A	2.65%	2.53%	17.32%
P/E Ratio	N/A	799.72	274.64	26.20
Price / Sales	0.30	755.20	608.57	91.20
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	1.88	10.68	11.26	6.40
Net Income	-$3.17M	$2.83B	$3.49B	$381.07M
7 Day Performance	-3.17%	-2.20%	-1.68%	-0.66%
1 Month Performance	-7.92%	-6.55%	-5.97%	-4.51%
1 Year Performance	-69.42%	-4.52%	8.11%	1.82%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	0.0685 of 5 stars	$1.22 -1.6%	N/A	-68.9%	$5.94M	$19.53M	N/A	260
TXMD TherapeuticsMD	0.5331 of 5 stars	$2.03 -0.5%	N/A	+91.2%	$23.61M	$3.02M	N/A	420	News Coverage Gap Down
EGRX Eagle Pharmaceuticals	N/A	$0.95 -7.3%	N/A	-67.7%	$23.38M	$257.55M	0.81	100	Gap Down
UPC Universe Pharmaceuticals	0.7039 of 5 stars	$4.30 -4.9%	N/A	-4.5%	$22.71M	$17.86M	N/A	216
COCP Cocrystal Pharma	0.599 of 5 stars	$1.15 +2.7%	N/A	-5.4%	$21.58M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. TXMD, EGRX, UPC, COCP, and LPCN

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Sonoma Pharmaceuticals compare to Eagle Pharmaceuticals?

Summary

How does Sonoma Pharmaceuticals compare to Universe Pharmaceuticals?

Summary

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Summary

How does Sonoma Pharmaceuticals compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. TXMD, EGRX, UPC, COCP, and LPCN

How does Sonoma Pharmaceuticals compare to TherapeuticsMD?

Do analysts recommend TXMD or SNOA?

Which has more risk & volatility, TXMD or SNOA?

Is TXMD or SNOA more profitable?

Which has better valuation and earnings, TXMD or SNOA?

Do insiders & institutionals hold more shares of TXMD or SNOA?

Does the media favor TXMD or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Eagle Pharmaceuticals?

Which has more risk & volatility, EGRX or SNOA?

Do analysts recommend EGRX or SNOA?

Which has higher valuation and earnings, EGRX or SNOA?

Does the media favor EGRX or SNOA?

Do insiders & institutionals believe in EGRX or SNOA?

Is EGRX or SNOA more profitable?

Summary

How does Sonoma Pharmaceuticals compare to Universe Pharmaceuticals?

Do institutionals & insiders have more ownership in SNOA or UPC?

Does the media refer more to SNOA or UPC?

Which has more risk and volatility, SNOA or UPC?

Which has higher earnings and valuation, SNOA or UPC?

Do analysts recommend SNOA or UPC?

Is SNOA or UPC more profitable?

Summary

How does Sonoma Pharmaceuticals compare to Cocrystal Pharma?

Which has more risk and volatility, COCP or SNOA?

Do analysts prefer COCP or SNOA?

Is COCP or SNOA more profitable?

Do institutionals & insiders hold more shares of COCP or SNOA?

Does the media refer more to COCP or SNOA?

Which has preferable earnings and valuation, COCP or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Lipocine?

Does the media favor LPCN or SNOA?

Do insiders & institutionals believe in LPCN or SNOA?

Which has stronger earnings and valuation, LPCN or SNOA?

Which has more risk and volatility, LPCN or SNOA?

Do analysts prefer LPCN or SNOA?

Is LPCN or SNOA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools